Posters

Filters

Clear Filters
All Days Sun, Sep 27 Mon, Sep 28 Tue, Sep 29

Sunday, September 27

3:00 PM - 4:00 PM ET

2281 - Early MRI Radiomics-Based Triage Model Predicts Response and Survival after Bevacizumab in Recurrent Glioblastoma
Speaker: You, Weir Chiang, MD, PhD - Taichung Veterans General Hospital, Taichung, Taichung
3:00 PM - 4:00 PM ET

2282 - Serplulimab plus Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Single-Arm, Multicenter, Phase I/II Trial (SCR-ESCC-02)
Speaker: Yu, Wen, MD, PhD - Shanghai Chest Hospital Shanghai Jiao Tong University, Shanghai, Shanghai
3:00 PM - 4:00 PM ET

2283 - Radiosensitization and Active Antitumor Effect of Antibody-Drug Conjugates on Brain Metastases after Whole Brain Radiation
Speaker: Yu, Yao, MD - Memorial Sloan Kettering Cancer Center, New York, NY
3:00 PM - 4:00 PM ET

2284 - Association Between Frailty and Progression Free Survival in Glioblastoma
Speaker: Yukselen Guney, Yildiz, MD, PhD - Ankara Onkoloji Hospital, Ankara, Ankara
3:00 PM - 4:00 PM ET

2285 - N-Terminal Androgen Receptor Antagonists Offer Superior Tumor Suppression on Glioblastoma than C-Terminal Inhibitors
Speaker: Zhang, Chi, MD, PhD - Mayo Clinic Arizona, Phoenix, AZ
3:00 PM - 4:00 PM ET

2286 - Induction Chemotherapy Exposure as a Determinant of Local Control Independent of Radiation Modality in Pancreatic Cancer
Speaker: Zhang, Ella, BS - Yale School of Medicine, New Haven, CT
3:00 PM - 4:00 PM ET

2287 - Neoadjuvant Short-Course Radiotherapy Combined with Immunochemotherapy vs. Chemotherapy Alone in pMMR Colon Cancers: The TORCH-C Randomized Phase 2 Clinical Trial
Speaker: Zhang, Hui, PhD - Fudan University, Shanghai, Shanghai
3:00 PM - 4:00 PM ET

2288 - Efficacy and Prognosis of Neoadjuvant Chemoimmunotherapy Followed by Concurrent Chemoradiotherapy in Unresectable Esophageal Cancer: The First Single-Center Real-World Study
Speaker: Zhang, Xiaofei, MD - Shanghai cancer hospital, Shanghai, shanghai
3:00 PM - 4:00 PM ET

2289 - Organ Preservation-First Strategy Following Total Neoadjuvant Chemoradiotherapy for MRI-Defined Low-Risk Rectal Cancer: Early Results from a Prospective, Single-Center, Phase II Trial (PKUCH-R08)
Speaker: Zhang, Yangzi, MD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, Beijing
3:00 PM - 4:00 PM ET

2290 - Integrative Radiogenomic Analysis Identifies Imaging-Linked Molecular Subtypes and Drivers of Heterogeneity in Pancreatic Adenocarcinoma
Speaker: Zheng, Dandan, PhD - University of Rochester, Rochester, NY
3:00 PM - 4:00 PM ET

2291 - Real-World Survival Outcomes across Radiotherapy-Based Care Pathways for Esophageal Cancer: A Population-Based Study from Hong Kong CADRS
Speaker: Zhong, Sijin, MD - National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing
3:00 PM - 4:00 PM ET

2292 - Radiotherapy plus Chemoimmunotherapy Followed by Surgery for Gastric Cancer with Limited Lymph Node Metastases: Preliminary Results from the MIRACLE-G Study
Speaker: Zhou, Meng-long, MD - Fudan University Shanghai Cancer Center, Shanghai, Shanghai